This activity is supported by an educational grant from Takeda Pharmaceuticals International, Inc., U.S. Region, and Orexigen Therapeutics, Inc., and jointly sponsored by Medical Education Resources (MER), Nurse Practitioner Associates for Continuing Education (NPACE), and Haymarket Medical Education (HME).
Harold E. Bays, MD
Louisville Metabolic and Atherosclerosis Research Center Inc.
Release Date: October 15, 2014
Expiration Date: October 14, 2015
Estimated time to complete the educational activity: 30 minutes
Statement of Need: As understandings of the potential underlying causes of obesity have increased, a number of new therapeutic targets have emerged. Three novel weight-loss medications were approved within the last 2 years and others are in clinical development.These options differ significantly in terms of their mechanisms of action, potential side effects, and contraindications. Thus, it is important that clinicians are knowledgeable about the safety and efficacy profiles of these medications, and how to select appropriate candidates for pharmacologic therapy.
Target Audience: This activity has been designed to meet the educational needs of primary-care physicians, physician assistants, nurse practitioners, and other clinicians with an interest in obesity prevention and management.
Learning Objectives: After completing the activity, the participant should be better able to:
- Describe the individual mechanisms of action and safety and efficacy profiles of traditional, new, and emerging pharmacologic agents for obesity
- Formulate multimodal interventions, including pharmacologic agents, that are customized to the characteristics/comorbidities of each overweight/obese patient
Physician Credit: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). MER is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation: MER designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity
Nursing Credit: Nurse Practitioner Associates for Continuing Education (NPACE) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).
Credit Designation: NPACE designates this enduring material for amaximum of 0.5 contact hours of credit. Participants should only claimcredit commensurate with the extent of their participation in the activity.
MER ensures balance, independence, objectivity, and scientific rigor in all oureducational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a CME activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality CME activities that promote improvements or quality in health care and not the business interest of a commercial interest.
It is the policy of Nurse Practitioner Associates for Continuing Education to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. All faculty participating in our programs are expected to disclose any relationships they may have with commercial companies whose products or services may be mentioned so that the participants may evaluate the objectivity of the presentations. In addition, any discussion of off-label, experimental, or investigational use of drugs or devices will be disclosed by faculty.The faculty reported the following financial relationships withcommercial interests whose products or services may be mentioned inthis CME/CE activity:
Harold E. Bays, MD, has received research funding from Alere, Amarin, Amgen, Ardea Inc., Boehringer Ingelheim, Bristol-Myers Squibb, California Raisin Board, Catabasis, Cymabay, Eisai, Elcelyx, Eli Lilly, Esperion, Forest, Gilead, Given, GlaxoSmithKline, Hanmi, High Point Pharmaceuticals, LLC, Hisun, Hoffmann-La Roche, Home Access, Isis, Janssen, Merck, Micropharma Limited, Nektar, Novartis, Novo Nordisk, Omthera, Orexigen Therapeutics, Pfizer, Pronovo, Regeneron, Sanofi, Takeda, TIMI, Transtech Pharma, Inc., Trygg Pharmaceuticals, VIVUS, and WPU. He has received honoraria from Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Catabasis, Daiichi Sankyo, Inc., Eisai, Isis, Merck, Omthera, Pronovo, Sanofi, Shire, Vivus and WPU.
Krista Sierra, Susan Basilico, Sonja K. Billes, and Sarah Taegder, all of HME, have no financial relationships to disclose.
MER Content Manager has no financial relationships to disclose.
NPACE Planning Committee has no financial relationships to disclose.
Method of Participation: There are no fees for participating in and receiving CME/CE credit for this activity. During the period of October 15, 2014 to October 14, 2015 participants must:
- Read the learning objectives and faculty disclosures;
- Study the educational activity;
- Submit the post-test online (clinicians may register at www.mycme.com);
- Complete the evaluation form online
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
Disclaimer: The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of MER, NPACE, or HME. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MER, NPACE, or HME. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.